FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
The agency has long had strict rules about approving drugs that were tested solely overseas, requiring that the data be applicable to patients and medical practice in the United States, that the investigators had “recognized competence” and that the agency be able to validate the data. In a withering critique of Lilly’s submission on this…
Details